Emerging retatrutide, a twin -action drug targeting simultaneously GLP-1 and GIP receptors, is creating considerable buzz within the healthcare community. Early clinical trials have shown substantial losses in physical weight and advancements in health markers for patients with obesity . Researchers believe this unique approach may represent a k… Read More